Tata Midcap Growth Fund turns a Rs 1,000 monthly SIP into Rs 1 crore in 30 years. Explore its top holdings, risk profile, and ...

The urinary tract infection (UTI) treatment market is estimated to be valued at USD 11.24 billion in 2024. The scope for urinary tract infection (UTI) treatment is predicted to rise at a CAGR of 1.9% ...

Shares of Aurobindo Pharma Ltd fell 2.5 percent to Rs 1,161 in morning trade on May 28 after the company reported an 11 percent increase in revenue and a marginal drop in net profit in the March ...

Aurobindo Pharma's stock experienced a price fall during today's trading session. The stock is currently trading at Rs 1,167.10, reflecting a decrease of 2.02%. This movement places Aurobindo ...

On a fiscal year basis (FY25), Aurobindo Pharma’s PAT increased 10% y-o-y to ₹3,484 crore from ₹3,169 crore in FY24, showing better full year profitability. Annual income at the company ...

GIC Re on Monday posted a 17% decline in net profit to ₹2,183 crore for the fourth quarter ended March 2025. The state-owned ...

The purpose of the incorporation of this wholly owned subsidiary is to expand the biopharma products business in Europe.

Aurobindo Pharma reported a consolidated revenue increase of 10.6% year-on-year, reaching Rs 8,382 crore in Q4 FY25.

Aurobindo Pharma will release its next earnings report on Aug 07, 2025. What Is Aurobindo Pharma’s Revenue Forecasts For Upcoming Quarters? Aurobindo Pharma’s revenue forecast is 86.01B.

Q4 Results Today: Indian markets are set for an active start to the week as more than 200 companies are set ... the most closely watched names are Aurobindo Pharma, Gillette India, Sundaram ...

The founding ten companies all have members on the Board of Directors, but the membership to the non-profit organisation will be open to all pharma and biotech companies who can contribute to and ...